Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3754919 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL19402494 | 0.75 | ALDH1A1 (0.58) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL2372443 | 0.74 | OPRM1 (0.52) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL19926219 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL12861292 | 0.73 | ALDH1A1 (0.57) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL15614663 | 0.73 | MTNR1A (0.48) | ALDH1A1 | |
| SCHEMBL30142479 | 0.73 | KMT2A (0.59) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL19926220 | 0.73 | KMT2A (0.59) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL19925979 | 0.73 | OPRM1 (0.67) | ALDH1A1KMT2AOPRM1OPRD1MEN1 | |
| SCHEMBL19397729 | 0.72 | ALDH1A1 (0.56) | ALDH1A1KMT2AOPRM1OPRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | ALDH1A1 1048/4885KMT2A 943/4885OPRM1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.